Previous Close | 9.62 |
1-Year Change | -61.27% |
6-Months Change | -57.23% |
3-Months Change | -40.1% |
Moving Avg (50d) | 12.2593 |
Moving Avg (200d) | 19.4488 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.857B |
Beta (3-Years) | 2.08 |
Revenue Growth (ttm) | -55.51% |
Net Profit Margin (ttm) | -4867.77% |
Return On Assets (ttm) | -37.19% |
EPS (ttm) | -5.33 |
PE Ratio (ttm) | -1.8 |
Dividend Yield | % |
Asset Description: | Intellia Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2025-01-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
9.812 | 10.101 | 10.293 | 10.582 | 11.063 | 11.544 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.